


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Cassia Regional Medical Center 2. 1501 Hiland Avenue Burley, ID 83318		In accordance with letter dated September 06, 2017.	4. Expiration Date: August 31, 2018	
			5. Docket No.: 030-32333 Reference No.:	
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200		7. Chemical and/or physical form A. Any B. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200.
				
<div>★ ★ ★</div> CONDITIONS <div>★ ★ ★</div>				
10. Licensed material may be used or stored at the licensee's facilities located at 1501 Hiland Avenue, Burley, Idaho, 83318.				
11. The Radiation Safety Officer (RSO) for this license is Kelli J. Silverstrim.				

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

11-27393-01

Docket or Reference Number

030-32333

Amendment No. 20

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users and/or authorized nuclear pharmacists in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized UsersMaterial and Use

John M. Jacobs, M.D.

35.100; 35.200

Spencer J. Robertson, M.D.

35.100; 35.200

Benjamin H.J. Gordon, M.D.

35.100; 35.200

Kenneth M. Handlon, M.D.

35.100; 35.200

Wendell C. Johnson, M.D.

35.100; 35.200

Scott D. Kendell, M.D.

35.100; 35.200

Kenneth J. Nowers, M.D.

35.100; 35.200

Fernando J. Rodriguez, M.D.

35.100; 35.200

Jonathan S. Shakespear, M.D.

35.100; 35.200

Michael S. Webb, M.D.

35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
11-27393-01

Amendment No. 20

Docket or Reference Number
030-32333

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated May 28, 2008 (ML081720161)
- B. Letter dated May 21, 2012 (ML12165A632)
- C. Letter dated July 19, 2012 (ML12205A185)
- D. Letter dated December 10, 2013 (ML13361A075)
- E. Letter dated January 31, 2014 with enclosures (ML14057A682)
- F. E-mail dated April 23, 2014 (ML14153A618)
- G. Letter dated March 10, 2015 (ML15120A580)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 27, 2017By: /RA/Roberto J. Torres
Region IV